Results just in: Starpharma Holdings Limited (ASX:SPL) shares lose ground

The Starpharma Holdings Limited (ASX: SPL) share price fell 1% to $1.12 after the company published its annual results to the market this morning. Revenue rose 34% to $4.8 million and the net loss after tax decreased to $10.3 million.

Starpharma did not declare a dividend and reported a net loss after tax of 3 cents per share. The company ended the year with $51 million in cash and no debt.

During the year, Starpharma made progress on several of its clinical trials, completing a Phase 1 trial for its treatment DEP docetaxel, and commencing a Phase 2 trial in the UK.

The company also demonstrated the efficacy of its VivaGel BV in phase 3 trials, progressed towards regulatory approval in the USA, and achieved marketing approval for VivaGel in Australia. There are several other treatments in varying stages of research and development.

In 2019, Starpharma expects to begin commercialising its VivaGel product and delivering its first revenues. This will likely require heavy investment in sales staff and support infrastructure, however Starpharma is well funded and likely able to continue operating for up to 3 years or more before requiring any additional cash. With its losses in prior years, Starpharma may also be able to call on a substantial tax benefit (from unused tax losses) if it becomes profitable in time, although no deferred tax asset appears to be recognised currently.

While Starpharma is well funded, it is still a highly risky and unprofitable company and suitable only for risk-tolerant investors who are cautious in their position sizing.

The ASX small cap up 285% with no sign of stopping...

One Australian company has developed a state of the art device that's revolutionizing hospitals all over the world. Even better, this device is so profitable that the company rakes in 90% margins. That's a lot of cash. So no wonder the stock's up 285% since 2008 – with no signs of stopping...

To discover the name and code, simply click the link below. You'll discover our expert's #1 medical technology pick... and you can decide for yourself whether to get invested today.

Click here to claim your free report.

Motley Fool contributor Sean O'Neill has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.